LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LondonWallet
No Result
View All Result

Coca-Cola’s stock jumps after profit and revenue beat expectations as price and volume rose

Clyde Edgerton by Clyde Edgerton
October 24, 2023
in Markets
Coca-Cola’s stock jumps after profit and revenue beat expectations as price and volume rose
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter


You might also like

Trump's approval holds steady despite unpopular policies, per new NYT poll

Trump is selling a strong economy. Voters aren’t buying it.

Former Trump statistics chief slams Friday firing of Erika McEntarfer

Shares of Coca-Cola Co.
KO,
-0.90%
jumped 2.4% in premarket trading Tuesday, after the beverage giant beat third-quarter profit expectations and provided an upbeat outlook, as unit case volume returned to growth. Net income rose to $3.09 billion, or 71 cents a share, from $2.83 billion, or 65 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 74 cents beat the FactSet consensus of 69 cents. Revenue grew 8.0% to $11.95 billion, above the FactSet consensus of $11.44 billion. Price and mix increased 9%, while concentrate sales and unit case volume rose 2%, after unit case volume was flat in the second quarter. For 2023, the company expects adjusted EPS growth of 7% to 8% from $2.48 in 2022, which implies EPS of $2.65 to $2.68. That’s above the current FactSet consensus of $2.64. The stock has dropped 13.4% over the past three months through Monday, while the Dow Jones Industrial Average
DJIA,
-0.58%
has lost 7.0%.



Source link

Share30Tweet19
Previous Post

Bitcoin continues its gains today with a 2.5% rise after more positive sentiment in the markets

Next Post

AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

Clyde Edgerton

Clyde Edgerton

Recommended For You

Trump's approval holds steady despite unpopular policies, per new NYT poll
Markets

Trump's approval holds steady despite unpopular policies, per new NYT poll

September 30, 2025
Trump is selling a strong economy. Voters aren’t buying it.
Markets

Trump is selling a strong economy. Voters aren’t buying it.

September 13, 2025
Former Trump statistics chief slams Friday firing of Erika McEntarfer
Markets

Former Trump statistics chief slams Friday firing of Erika McEntarfer

August 3, 2025
Inside Trump’s chainsaw-wielding approach to one corner of government contracting
Markets

Inside Trump’s chainsaw-wielding approach to one corner of government contracting

May 25, 2025
Next Post
AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

Related News

Just a moment…

Just a moment…

May 30, 2023
U.S. stocks open mostly lower after Labor Day weekend

U.S. stocks open mostly lower after Labor Day weekend

September 5, 2023
Transfer news LIVE: All the latest news, rumours and confirmed moves

Transfer news LIVE: All the latest news, rumours and confirmed moves

July 23, 2023

Browse by Category

  • Business Finance
  • Crypto
  • Industries
  • Investing
  • Markets
  • Opinion
  • Real Estate
  • UK

London Wallet

Read latest news about finance, business and investing

  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2025 London Wallet - All Rights Reserved!

No Result
View All Result
  • Checkout
  • Contact
  • Home
  • Login/Register
  • My account
  • Privacy Policy
  • Terms and Conditions

© 2025 London Wallet - All Rights Reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?